Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at Wall Street Zen

Investment analysts at Wall Street Zen started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS opened at $0.55 on Wednesday. Marinus Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $1.97. The firm has a 50-day simple moving average of $0.55 and a 200-day simple moving average of $0.48. The company has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Large investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in Marinus Pharmaceuticals in the fourth quarter valued at about $54,000. JPMorgan Chase & Co. boosted its holdings in Marinus Pharmaceuticals by 1,968.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares in the last quarter. Deltec Asset Management LLC purchased a new stake in Marinus Pharmaceuticals in the 4th quarter valued at approximately $107,000. Finally, XTX Topco Ltd increased its position in Marinus Pharmaceuticals by 1,564.7% during the 4th quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 206,614 shares during the period. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.